Cargando…
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450548/ https://www.ncbi.nlm.nih.gov/pubmed/32864131 http://dx.doi.org/10.1186/s40364-020-00209-0 |